Nova Eye Medical Limited announced the establishment of AlphaRET Pty Ltd. support the commercial development of its 2RT® asset. 2RT® is the Company's proprietary minimally invasive nano-pulse ophthalmic laser therapy which, in the 2018 Phase 2 "LEAD" clinical study, demonstrated efficacy in a subset of patients in the treatment of intermediate age-related macular degeneration (iAMD). The establishment of AlphaRET, a wholly owned subsidiary of Nova Eye Medical Limited, will enable the Company to focus its development activities for 2RT®. It also clearly delineates the 2RT® project from the Company's core business, which is focused on glaucoma treatment technologies. 2RT® is based on seminal laboratory investigations performed by world-renowned retinal expert Prof. John Marshall PhD, FRCPath, FMedDSci (Institute of Ophthalmology, University College London, UK). Prof. Marshall is actively involved in the 2RT® project and is a Board member of AlphaRET. In the immediate term AlphaRET will prioritise the USA regulatory pathway for 2RT®, which includes the filing of an Investigational Device Exemption (IDE) with the US Food and Drug Administration (FDA) for a major clinical study. The aim of the study will be to provide statistically significant clinical evidence that 2RT delays the progression on iAMD and thereby obtain clearance from the FDA to treat patients.